DAVID W GRYSKA

CIK 1202335 · Executive Vice President, CFO · last filed 2026-06-15

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$2.56M

Companies

11

Total Filings

117

Lifetime Open-Market Net

-$23.62M

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
DFTX Director 19,900 $44.39 $883.4K $0 1 2026-06-15
FBRX Director 5,941 $76.61 $455.1K $0 6 2026-06-02
Definium Therapeutics, Inc. (MNMD) Delisted Director 19,851 $15.00 $297.8K $38.9K 5 2025-06-16
Seagen Inc. (SGEN) Delisted Director 0 $228.74 $0 -$9.71M 42 2023-12-15
AERIE PHARMACEUTICALS INC (AERI) Delisted Director 0 $15.25 $0 $0 7 2022-11-21
GW PHARMACEUTICALS PLC (GWPH) Delisted Director $218.96 $0 2 2021-02-24
PDL BIOPHARMA, INC. (PDLI) Delisted Director 1,387 -$925.8K 14 2020-12-31
INCY Executive Vice President, CFO 10,235 $119.80 $1.23M -$9.18M 17 2018-07-18
HYPERION THERAPEUTICS INC (HPTX) Delisted Director $0 1 2013-05-01
CELGENE CORP /DE/ (CELG) Delisted Chief Financial Officer 7,526 -$3.84M 20 2010-07-15
COTHERIX INC (CTRX) Delisted Director $0 1 2007-01-10

Recent Filings · Page 2 of 12

117 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2023-08-02 FBRX Grant (A) +148,514 $150.0K EDGAR
2023-06-23 Definium Therapeutics, Inc. (MNMD) Delisted Grant (A) +13,851 $0 EDGAR
2023-06-02 Seagen Inc. (SGEN) Delisted Grant (A) +2,044 $0 EDGAR
2023-02-15 Seagen Inc. (SGEN) Delisted Exer (M) +8,750 $321.1K EDGAR
2023-01-12 FBRX Grant (A) $0 EDGAR
2022-11-21 AERIE PHARMACEUTICALS INC (AERI) Delisted Disp (D) −13,491 -$205.7K EDGAR
2022-11-15 Seagen Inc. (SGEN) Delisted Sell (S) −7,500 -$968.2K EDGAR
2022-06-13 AERIE PHARMACEUTICALS INC (AERI) Delisted Grant (A) +6,245 $0 EDGAR
2022-05-17 Seagen Inc. (SGEN) Delisted Grant (A) +1,503 $0 EDGAR
2022-04-21 Seagen Inc. (SGEN) Delisted Mixed -$495.5K EDGAR
Showing 1120 of 117
Page 2 of 12
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.